DDrare: Database of Drug Development for Rare Diseases

Searched query = "Angelman syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Aknemin; Aknemin 50; Betaine; Carbidopa; Creatine; GABOXADOL MONOHYDRATE; GTX-102; Gaboxadol; Gaboxadol monohydrate 0.5 mg; Gaboxadol monohydrate 0.5 mg (intended commercial formulation); Gaboxadol monohydrate 0.5 mg capsule; Gaboxadol monohydrate 2 mg; Gaboxadol monohydrate 2 mg (intended commercial formulation); Gaboxadol monohydrate 2 mg capsule; Gaboxadol monohydrate 5 mg; Gaboxadol monohydrate 5 mg (intended commercial formulation); Levodopa; Levodopa/Carbidopa (4:1); MINOCYCLINE; MINOCYCLINE HYDROCHLORIDE; Metafolin; Minocycline; Nutritional Formulation Containing Exogenous Ketones; OV101; OV101 Regimen 1; OV101 regimen 2; RO7248824; RO7248824/F02-01; RO7248824/F03-01 (Diluent for RO7248824/F02-01; Vitamin B12

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02056665 (ClinicalTrials.gov)	January 2014	5/2/2014	Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome	Randomized Clinical Trial, Placebo Compared to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome	Angelman Syndrome	Drug: MINOCYCLINE;Drug: PLACEBO (for Minocycline)	Puerta de Hierro University Hospital	NULL	Completed	6 Years	30 Years	Both	32	Phase 2	Spain
2	EUCTR2013-002154-67-ES (EUCTR)	26/12/2013	16/09/2013	STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MINOCYCLINE IN ANGELMAN SYNDROME (A-MANECE STUDY)	RANDOMIZED CLINICAL TRIAL, PLACEBO COMPARED TO EVALUATE THE EFFICACY AND SAFETY OF MINOCYCLINE IN ANGELMAN SYNDROME (A-MANECE STUDY) - A-MANECE	Angelman Syndrome MedDRA version: 16.0;Level: PT;Classification code 10049004;Term: Angelman's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Aknemin 50 INN or Proposed INN: MINOCYCLINE Other descriptive name: MINOCYCLINE HYDROCHLORIDE	Dra. Cristina Avendaño Solá	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Spain
3	NCT01531582 (ClinicalTrials.gov)	April 2012	5/2/2012	Minocycline in the Treatment of Angelman Syndrome	The Efficacy of Minocycline in the Treatment of Angelman Syndrome	Angelman Syndrome	Drug: minocycline	University of South Florida	NULL	Active, not recruiting	4 Years	12 Years	Both	25	N/A	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02056665
(ClinicalTrials.gov)

January 2014

5/2/2014

Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome

Randomized Clinical Trial, Placebo Compared to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome

Angelman Syndrome

Drug: MINOCYCLINE;Drug: PLACEBO (for Minocycline)

Puerta de Hierro University Hospital

NULL

Completed

6 Years

30 Years

Both

Phase 2

Spain

EUCTR2013-002154-67-ES
(EUCTR)

26/12/2013

16/09/2013

STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MINOCYCLINE IN ANGELMAN SYNDROME (A-MANECE STUDY)

RANDOMIZED CLINICAL TRIAL, PLACEBO COMPARED TO EVALUATE THE EFFICACY AND SAFETY OF MINOCYCLINE IN ANGELMAN SYNDROME (A-MANECE STUDY) - A-MANECE

Angelman Syndrome
MedDRA version: 16.0;Level: PT;Classification code 10049004;Term: Angelman's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Aknemin 50
INN or Proposed INN: MINOCYCLINE
Other descriptive name: MINOCYCLINE HYDROCHLORIDE

Dra. Cristina Avendaño Solá

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Spain

NCT01531582
(ClinicalTrials.gov)

April 2012

5/2/2012

Minocycline in the Treatment of Angelman Syndrome

The Efficacy of Minocycline in the Treatment of Angelman Syndrome

Angelman Syndrome

Drug: minocycline

University of South Florida

NULL

Active, not recruiting

4 Years

12 Years

Both

N/A

United States